#First period of reactivity trial#

0138).ĬNM-Au8 is currently in development and not indicated for any particular disease. 0197) and difference of mMSFC average ranked sum score (13.4 95% CI, 2.8-23.9 P =. In addition, CNM-Au8 showed significant outcomes on mean difference of standardized modified MS Functional Composite (mMSFC) score (0.28 95% CI, 0.04-0.52 P =. 056) in best corrected-low contrast letter acuity, the primary end points, vs placebo. Over a 48-week period, treatment with the agent resulted in a least square mean difference of 3.13 (95% CI, –0.08 to 6.33 P =.

#First period of reactivity trial#

The therapy showed significant effects vs placebo in the phase 2 VISIONARY-MS study (NCT03536559), a double-blind, multicenter trial of patients with stable relapsing MS. One agent in development, CNM-Au8 (Clene Nanomedicine), may serve as a potentially beneficial adjuvant option for patients who are on stable DMTs.ĬNM-Au8, an oral suspension of catalytically-active gold nanocrystals, supports brain energy metabolism resulting in neuroprotection and remyelination in preclinical models. There are over 20 disease-modifying treatments (DMTs) for relapsing forms of the disease, forcing conversations to shift from addressing relapses to stopping neurodegeneration and ongoing lesion burden. Once perceived as an extremely debilitating disease, advances in therapeutics for multiple sclerosis (MS) have substantially lowered the risk of relapses for patients and improved quality of life.

We’ll give them an anti-inflammatory therapy, but also a neuroprotective therapy, and potentially a proremyelinating therapy from day 1 of the disease because that’s when a lot of the damage is done.' 'In an ideal world, when we see a patient and make a diagnosis of MS, we put them on a dual therapy.